In a report released yesterday, Scott Bardo from Berenberg Bank maintained a Buy rating on LivaNova PLC (LIVN), with a price target of $132. The company’s shares closed yesterday at $94.28.
Bardo has an average return of 36.4% when recommending LivaNova PLC.
According to TipRanks.com, Bardo is ranked #495 out of 5233 analysts.
Currently, the analyst consensus on LivaNova PLC is a Strong Buy with an average price target of $132.50, representing a 40.5% upside. In a report issued on February 19, Piper Jaffray also maintained a Buy rating on the stock with a $145 price target.
See today’s analyst top recommended stocks >>
Based on LivaNova PLC’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $297 million and GAAP net loss of $211 million. In comparison, last year the company had a GAAP net loss of $112 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the Cardiac Surgery and Neuromodulation, and Other Corporate segments.
